Logo image of IBAB.BR

ION BEAM APPLICATIONS (IBAB.BR) Stock Fundamental Analysis

EBR:IBAB - Euronext Brussels - BE0003766806 - Common Stock - Currency: EUR

11.37  +0.01 (+0.09%)

Fundamental Rating

4

Overall IBAB gets a fundamental rating of 4 out of 10. We evaluated IBAB against 54 industry peers in the Health Care Equipment & Supplies industry. IBAB has a medium profitability rating, but doesn't score so well on its financial health evaluation. IBAB has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

IBAB had positive earnings in the past year.
IBAB had a negative operating cash flow in the past year.
IBAB had positive earnings in 4 of the past 5 years.
Of the past 5 years IBAB 4 years had a positive operating cash flow.
IBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFIBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 1.32%, IBAB is in line with its industry, outperforming 50.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 8.70%, IBAB is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
With an excellent Return On Invested Capital value of 16.12%, IBAB belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IBAB is below the industry average of 8.28%.
The last Return On Invested Capital (16.12%) for IBAB is above the 3 year average (4.60%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.32%
ROE 8.7%
ROIC 16.12%
ROA(3y)0.05%
ROA(5y)1.64%
ROE(3y)-0.09%
ROE(5y)5.81%
ROIC(3y)4.6%
ROIC(5y)5.51%
IBAB.BR Yearly ROA, ROE, ROICIBAB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20

1.3 Margins

IBAB has a Profit Margin (1.69%) which is comparable to the rest of the industry.
Looking at the Operating Margin, with a value of 5.96%, IBAB is in line with its industry, outperforming 51.85% of the companies in the same industry.
IBAB's Operating Margin has declined in the last couple of years.
IBAB's Gross Margin of 34.19% is on the low side compared to the rest of the industry. IBAB is outperformed by 75.93% of its industry peers.
In the last couple of years the Gross Margin of IBAB has declined.
Industry RankSector Rank
OM 5.96%
PM (TTM) 1.69%
GM 34.19%
OM growth 3Y-48.42%
OM growth 5Y-3.26%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.41%
GM growth 5Y-3.03%
IBAB.BR Yearly Profit, Operating, Gross MarginsIBAB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IBAB is creating value.
Compared to 1 year ago, IBAB has about the same amount of shares outstanding.
Compared to 5 years ago, IBAB has less shares outstanding
The debt/assets ratio for IBAB is higher compared to a year ago.
IBAB.BR Yearly Shares OutstandingIBAB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
IBAB.BR Yearly Total Debt VS Total AssetsIBAB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 1.40, we must say that IBAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IBAB (1.40) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.32 indicates that IBAB is not too dependend on debt financing.
IBAB's Debt to Equity ratio of 0.32 is in line compared to the rest of the industry. IBAB outperforms 57.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 1.4
ROIC/WACC2.31
WACC6.98%
IBAB.BR Yearly LT Debt VS Equity VS FCFIBAB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.96 indicates that IBAB may have some problems paying its short term obligations.
With a Current ratio value of 0.96, IBAB is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
A Quick Ratio of 0.64 indicates that IBAB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.64, IBAB is doing worse than 75.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.64
IBAB.BR Yearly Current Assets VS Current LiabilitesIBAB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 139.84% over the past year.
The Revenue has grown by 25.66% in the past year. This is a very strong growth!
The Revenue has been growing by 10.74% on average over the past years. This is quite good.
EPS 1Y (TTM)139.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.21%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y11.18%
Revenue growth 5Y10.74%
Sales Q2Q%21.86%

3.2 Future

IBAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 85.23% yearly.
IBAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.44% yearly.
EPS Next Y149.04%
EPS Next 2Y120.85%
EPS Next 3Y85.23%
EPS Next 5YN/A
Revenue Next Year13.58%
Revenue Next 2Y15.17%
Revenue Next 3Y12.74%
Revenue Next 5Y4.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IBAB.BR Yearly Revenue VS EstimatesIBAB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
IBAB.BR Yearly EPS VS EstimatesIBAB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 42.11 indicates a quite expensive valuation of IBAB.
IBAB's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of IBAB to the average of the S&P500 Index (28.89), we can say IBAB is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 11.17, the valuation of IBAB can be described as reasonable.
Based on the Price/Forward Earnings ratio, IBAB is valued cheaper than 85.19% of the companies in the same industry.
IBAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.98.
Industry RankSector Rank
PE 42.11
Fwd PE 11.17
IBAB.BR Price Earnings VS Forward Price EarningsIBAB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

IBAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBAB is cheaper than 90.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.7
IBAB.BR Per share dataIBAB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

IBAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IBAB's earnings are expected to grow with 85.23% in the coming years.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y120.85%
EPS Next 3Y85.23%

More info and screens

1

5. Dividend

5.1 Amount

IBAB has a yearly dividend return of 0.94%, which is pretty low.
IBAB's Dividend Yield is a higher than the industry average which is at 2.15.
Compared to an average S&P500 Dividend Yield of 2.39, IBAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.94%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
IBAB.BR Yearly Dividends per shareIBAB.BR Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 0.05 0.1 0.15 0.2

5.3 Sustainability

IBAB pays out 122.81% of its income as dividend. This is not a sustainable payout ratio.
DP122.81%
EPS Next 2Y120.85%
EPS Next 3Y85.23%
IBAB.BR Yearly Income VS Free CF VS DividendIBAB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M
IBAB.BR Dividend Payout.IBAB.BR Dividend Payout, showing the Payout Ratio.IBAB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

ION BEAM APPLICATIONS

EBR:IBAB (3/27/2025, 10:34:30 AM)

11.37

+0.01 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-21 2024-11-21
Earnings (Next)03-20 2025-03-20/amc
Inst Owners29.32%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap344.28M
Analysts80
Price Target17.42 (53.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.94%
Yearly Dividend0.21
Dividend Growth(5Y)N/A
DP122.81%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.59%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-22.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.74%
Valuation
Industry RankSector Rank
PE 42.11
Fwd PE 11.17
P/S 0.74
P/FCF N/A
P/OCF N/A
P/B 3.81
P/tB 5.32
EV/EBITDA 8.7
EPS(TTM)0.27
EY2.37%
EPS(NY)1.02
Fwd EY8.95%
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS15.38
BVpS2.98
TBVpS2.14
PEG (NY)0.28
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.32%
ROE 8.7%
ROCE 21.5%
ROIC 16.12%
ROICexc 30.21%
ROICexgc 48.06%
OM 5.96%
PM (TTM) 1.69%
GM 34.19%
FCFM N/A
ROA(3y)0.05%
ROA(5y)1.64%
ROE(3y)-0.09%
ROE(5y)5.81%
ROIC(3y)4.6%
ROIC(5y)5.51%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)6.13%
ROCE(5y)7.35%
ROICexcg growth 3YN/A
ROICexcg growth 5Y69.4%
ROICexc growth 3YN/A
ROICexc growth 5Y38.7%
OM growth 3Y-48.42%
OM growth 5Y-3.26%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.41%
GM growth 5Y-3.03%
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA 0.74
Cap/Depr 86.14%
Cap/Sales 2.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.64
Altman-Z 1.4
F-Score5
WACC6.98%
ROIC/WACC2.31
Cap/Depr(3y)75.38%
Cap/Depr(5y)60.16%
Cap/Sales(3y)2.17%
Cap/Sales(5y)1.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.21%
EPS Next Y149.04%
EPS Next 2Y120.85%
EPS Next 3Y85.23%
EPS Next 5YN/A
Revenue 1Y (TTM)25.66%
Revenue growth 3Y11.18%
Revenue growth 5Y10.74%
Sales Q2Q%21.86%
Revenue Next Year13.58%
Revenue Next 2Y15.17%
Revenue Next 3Y12.74%
Revenue Next 5Y4.44%
EBIT growth 1Y254.31%
EBIT growth 3Y-42.65%
EBIT growth 5Y7.14%
EBIT Next Year543.3%
EBIT Next 3Y133.17%
EBIT Next 5YN/A
FCF growth 1Y-139.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.13%
OCF growth 3YN/A
OCF growth 5YN/A